Clinical Trial Update: The Safety and Dose Response to Single Anal Doses of NRL001 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and dose response of single doses of NRL001 in faecal incontinence; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Faecal Incontinence

Drugs mentioned

• NRL001

Snippet

Sponsor: Norgine | Conditions: Faecal Incontinence | Phase 1 | Status: COMPLETED